{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:12Z","timestamp":1786987452715,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272697"],"award-info":[{"award-number":["82272697"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902359"],"award-info":[{"award-number":["81902359"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY22H160020"],"award-info":[{"award-number":["LY22H160020"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LY24H160023"],"award-info":[{"award-number":["LY24H160023"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2022517591"],"award-info":[{"award-number":["2022517591"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.critrevonc.2026.105393","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:41:50Z","timestamp":1779838910000},"page":"105393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tertiary lymphoid structures (TLS): The mechanism hub and therapeutic target of neoadjuvant immunotherapy for hepatocellular carcinoma"],"prefix":"10.1016","volume":"224","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6995-6478","authenticated-orcid":false,"given":"Qingqing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changwei","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2026.105393_bib1","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2026.105393_bib2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2147\/ITT.S528709","article-title":"Advancing adjuvant immunotherapy in hepatocellular carcinoma: a comprehensive review","volume":"14","author":"Akabane","year":"2025","journal-title":"Immunotargets Ther."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105393_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/1744666X.2025.2568904","article-title":"Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: a comprehensive review","volume":"21","author":"Akabane","year":"2025","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105393_bib4","first-page":"749","article-title":"Folated-nanocarrier for paclitaxel drug delivery in leukemia cancer therapy","volume":"10","author":"Al-Musawi","year":"2018","journal-title":"J. Pharm. Sci. Res."},{"key":"10.1016\/j.critrevonc.2026.105393_bib5","doi-asserted-by":"crossref","DOI":"10.1063\/5.0092330","article-title":"Nanoformulation of intelligence polymeric nanocarrier for resveratrol targeted delivery and study its cytotoxic, apoptotic, and genetics effects in epidermoid carcinoma therapy","volume":"2437","author":"Alnasraui","year":"2022","journal-title":"AIP Conf. Proc."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105393_bib6","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO-24-02239","article-title":"Neoadjuvant nivolumab plus ipilimumab versus chemotherapy in resectable lung cancer","volume":"43","author":"Awad","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105393_bib7","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105393_bib8","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105393_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2018.09.003","article-title":"Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma","volume":"70","author":"Calderaro","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105393_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216837","article-title":"The emerging role of lactate in tumor microenvironment and its clinical relevance","volume":"590","author":"Chen","year":"2024","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105393_bib11","first-page":"1023","article-title":"Spatial VDJ reveals shared and distinct B cell clones across tumor regions","volume":"188","author":"Engblom","year":"2025","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105393_bib12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL clinical practice guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J. Hepatol."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105393_bib13","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105393_bib14","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: an intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"issue":"7791","key":"10.1016\/j.critrevonc.2026.105393_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","article-title":"B cells and tertiary lymphoid structures promote immunotherapy response","volume":"577","author":"Helmink","year":"2020","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105393_bib16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","article-title":"Neoadjuvant cabozantinib and nivolumab converts locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity","volume":"2","author":"Ho","year":"2021","journal-title":"Nat. Cancer"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105393_bib17","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.7150\/ijbs.117394","article-title":"Immunotherapy resistance in MASLD-related hepatocellular carcinoma: special immune microenvironment and gut microbiota","volume":"21","author":"Jin","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105393_bib18","first-page":"3210","article-title":"LIGHT-VTP induces tertiary lymphoid structures and promotes T cell-dependent antitumor immunity","volume":"81","author":"Johansson-Percival","year":"2021","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105393_bib19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2026.105393_bib20","article-title":"Hepatocellular carcinoma and liver transplant: What about neo- and adjuvant immunotherapy","author":"Khalaf","year":"2025","journal-title":"Hepatobiliary Pancreat. Dis. Int. (Forthcom. )."},{"key":"10.1016\/j.critrevonc.2026.105393_bib21","article-title":"Laparoscopic versus open surgery for liver resection: a multicenter cohort study","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105393_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jhep.2025.08.035","article-title":"Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration","volume":"84","author":"Lin","year":"2026","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105393_bib23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12943-025-02477-6","article-title":"Turning cold tumors into hot tumors to ignite immunotherapy","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105393_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/JS9.0000000000004998","article-title":"SPP1+ neutrophil and exhausted CD8\u207a T cells infiltration predicting the early recurrence of hepatocellular carcinoma patients after R0 resection","author":"Luo","year":"2026","journal-title":"Int. J. Surg. (Forthcom. )."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105393_bib25","first-page":"832","article-title":"Cancer-associated fibroblast subtypes and their spatial proximity to tertiary lymphoid structures in non-small cell lung cancer","volume":"43","author":"Nistic\u00f2","year":"2025","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105393_bib26","first-page":"213","article-title":"Metabolism in T cell activation and differentiation","volume":"51","author":"O\u2019Sullivan","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2026.105393_bib27","doi-asserted-by":"crossref","first-page":"13590","DOI":"10.3390\/ijms252413590","article-title":"Immune microenvironment and the effect of vascular endothelial growth factor inhibition in hepatocellular carcinoma","volume":"25","author":"Oura","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105393_bib28","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2025.03.005","article-title":"Neoadjuvant immune checkpoint therapy: enabling insights into fundamental human immunology and clinical benefit","volume":"43","author":"Pauken","year":"2025","journal-title":"Cancer Cell"},{"issue":"7791","key":"10.1016\/j.critrevonc.2026.105393_bib29","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","article-title":"B cells are associated with survival and immunotherapy response in sarcoma","volume":"577","author":"Petitprez","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2026.105393_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105248","article-title":"Viral hepatitis and immunotherapy outcome in advanced hepatocellular carcinoma: a comprehensive umbrella review of 15 meta-analyses","volume":"221","author":"Petrelli","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2026.105393_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1652433","article-title":"Intratumoral bacterial load and tertiary lymphoid structure density in hepatocellular carcinoma: association and prognostic significance","volume":"16","author":"Qu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105393_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101406","article-title":"Tertiary lymphoid structures and B cells: clinical impact and therapeutic modulation in cancer","volume":"48","author":"Saut\u00e8s-Fridman","year":"2020","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105393_bib33","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/s41423-025-01308-4","article-title":"Immune microenvironment in hepatocellular carcinoma: from pathogenesis to immunotherapy","volume":"22","author":"Seyhan","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105393_bib34","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41590-024-01992-w","article-title":"Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma","volume":"25","author":"Shu","year":"2024","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105393_bib35","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3390\/v17091255","article-title":"Hot and cold HCC: uncoupling viral oncogenesis and therapy","volume":"17","author":"Sneller","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.critrevonc.2026.105393_bib36","article-title":"Tertiary lymphoid structures in HCC: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy","author":"Su","year":"2025","journal-title":"Hepatol. (Forthcom. )"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105393_bib37","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors","volume":"2","author":"Vanhersecke","year":"2021","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105393_bib38","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7150\/thno.105423","article-title":"B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications","volume":"15","author":"Wu","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105393_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.461","article-title":"Unveiling the impact of tertiary lymphoid structures on immunotherapeutic responses of clear cell renal cell carcinoma","volume":"5","author":"Xu","year":"2024","journal-title":"MedComm"},{"issue":"10492","key":"10.1016\/j.critrevonc.2026.105393_bib40","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","article-title":"Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial","volume":"405","author":"Yau","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105393_bib41","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/ijms24032844","article-title":"Advances in the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"24","author":"Yin","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826002805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:28:43Z","timestamp":1782491323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826002805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":41,"alternative-id":["S1040842826002805"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105393","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tertiary lymphoid structures (TLS): The mechanism hub and therapeutic target of neoadjuvant immunotherapy for hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105393","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105393"}}